Herpes Virus Engineered to Fight Advanced Melanoma Shows Promising Results
A groundbreaking study demonstrates that a genetically engineered herpes simplex virus shows promising results in treating advanced melanoma, especially those resistant to immunotherapy, offering new hope for patients worldwide.
A novel approach using a genetically modified herpes simplex virus type 1 (HSV-1) is emerging as a promising treatment for advanced melanoma, particularly in cases resistant to traditional immunotherapy. While HSV-1 naturally causes cold sores, scientists have engineered it to target and destroy cancer cells without harming healthy tissue. Recent clinical trial outcomes published in the Journal of Clinical Oncology and presented at the 2025 American Society of Clinical Oncology annual meeting reveal significant tumor reduction in patients treated with this innovative therapy.
The study involved 140 patients with metastatic melanoma who had not responded effectively to prior treatments. Participants received a combination of a genetically engineered HSV-1, known as RP1, and immunotherapy drug nivolumab. Remarkably, about one-third of these patients experienced at least a 30% reduction in tumor size, and approximately 17% achieved complete tumor disappearance. These findings are particularly encouraging given that advanced melanoma often has limited treatment options and poor prognosis.
This new therapy leverages oncolytic viruses—viruses designed to infect and kill cancer cells while stimulating the immune system. RP1, the virus used in this trial, replicates within tumors, destroying cancer cells directly, and also prompts the immune system to attack other cancer sites throughout the body. Importantly, the treatment was well tolerated by patients, with manageable side effects.
The success of this approach has led to the launch of a Phase 3 clinical trial, named IGNYTE-3, aiming to include over 400 participants worldwide to confirm these promising results. Researchers believe that oncolytic viruses like RP1 could revolutionize cancer treatment by offering effective options for tumors that are difficult or impossible to reach with conventional therapies.
Source: https://medicalxpress.com/news/2025-07-cancer-herpes-virus-shown-effective.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Conflicted Attitudes in Arizona County Toward Medicaid Cuts Despite Political Leanings
Residents of Globe, Arizona, show mixed feelings about Medicaid cuts amid rising enrollment and political debates, highlighting the program's vital role in rural communities. Learn how local perspectives reveal the complex landscape of healthcare policy in conservative areas.
Enhancing Lung Cancer Radiation Therapy by Modulating Gut Microbiome
New research suggests that modulating the gut microbiome with antibiotics like vancomycin can significantly improve radiation therapy outcomes for lung cancer patients, boosting survival and reducing recurrence.
Insurance Status Significantly Impacts Likelihood of Critical Patient Transfers and Outcomes
A recent study reveals that uninsured and publicly insured critically ill patients are less likely to receive timely hospital transfers, leading to worse outcomes. Addressing insurance-related disparities is crucial for equitable critical care in the US.
Rising Concerns Over Nitrous Oxide Abuse at Concerts and Public Venues
Nitrous oxide abuse at concerts and music festivals is on the rise, posing serious health risks including addiction, brain damage, and death. Learn about the trending misuse and its dangerous consequences.